Trans-resveratrol and cis-resveratrol: differences, dosing and studies

Editorial draft. The evidence review corrected dosing statements and source attributions. Some mechanistic details remain open; clinical sign-off is pending.

Trans- and cis-resveratrol: different forms, different effects

Resveratrol is a polyphenol. Certain plants make it in response to stress, infection or UV radiation. It comes in two geometric forms, the isomers trans-resveratrol and cis-resveratrol. Their three-dimensional structures differ markedly, and so does their biological activity.

Trans-resveratrol is the form found in grape skins, Japanese knotweed (Polygonum cuspidatum) and other plant sources. It is the form used in most preclinical and clinical studies. The trans configuration allows the molecule to act on certain targets inside cells:

• Sirtuins (especially SIRT1), which regulate gene expression and DNA repair.

• AMPK, which controls cellular energy balance.

• Inflammatory signaling pathways, including NF-κB.

When researchers talk about resveratrol and longevity pathways, they are mostly referring to trans-resveratrol. Many of these findings come from cell and animal experiments. They prove neither that it extends life in humans nor that cis-resveratrol is biologically inactive.

The ratio of the two isomers depends on processing and storage, among other things. A clear statement of trans-resveratrol content makes products easier to compare. The cis share, however, cannot be reliably converted into a clinically effective dose.

Bioavailability: absorption in the gut and effect in the body

In a small study of six healthy adults, at least 70% of an oral 25 mg dose was absorbed. Even so, very little unchanged resveratrol could be detected in the blood: the gut and liver quickly convert it into sulfate and glucuronide compounds. Good absorption from the gut therefore does not automatically mean a high blood concentration of the parent compound. Primary study

Peak concentrations and half-life depend on the dose, the formulation and the measurement method. The sweeping claim that even gram doses produce only nanomolar blood levels is not correct: in a high-dose study, low micromolar concentrations were also measured. Blood levels alone, however, do not show whether a product has a health benefit. Study

Several approaches to improving bioavailability are being studied:

• Micronized formulations, which reduce particle size to increase surface area and absorption.

• Liposomal formulations, which may protect resveratrol from early breakdown and improve its transport into tissues.

• Co-administration with piperine (a compound in black pepper that inhibits drug-metabolizing enzymes).

A higher blood level from a special formulation does not yet mean a proven additional health benefit. It is no general reason to pay more for a pricier product.

Clinical studies: results and doses tested

A pharmacokinetic meta-analysis, published online in 2024 and in the journal’s 2025 volume, examined single doses of 25 to 5,000 mg in healthy adults. It describes uptake into the blood, not how well long-term use prevents disease. Source link

In the 2015 Alzheimer’s trial, 119 participants received resveratrol or placebo. The dose started at 500 mg per day and rose by 500 mg every 13 weeks up to 2,000 mg per day. Changes in individual biomarkers were not evidence of clinical improvement. Nausea, diarrhea and weight loss were among the common adverse events, and measured brain volume also decreased more on resveratrol. What this finding means remained unclear. Source link

A 2022 meta-analysis on type 2 diabetes found lower blood pressure and, at doses of 1,000 mg per day or more, lower fasting glucose. For waist circumference, triglycerides and HDL cholesterol, there was no statistically significant benefit. This shows neither a confirmed improvement in all metabolic markers nor a case for self-treatment. The studies differ considerably from one another. Source link

No reliable optimal dose can be derived from the studies. A general U-shaped dose-response curve is not adequately supported. In a separate dosing study, 2.5 and 5 g per day for 29 days caused mild to moderate gastrointestinal complaints. That argues against automatically assuming higher doses are better. Primary study

How resveratrol acts on AMPK, sirtuins and metabolism

Resveratrol acts through several interconnected signaling pathways. The best studied are AMPK (AMP-activated protein kinase) and the sirtuins, especially SIRT1. Through these pathways, cells sense their energy supply and adjust their metabolism.

AMPK activation

AMPK helps cells regulate their energy supply. When energy runs low, it promotes processes that provide ATP, among other things. Resveratrol influences this pathway in experimental models; the mechanisms depend on dose and experimental conditions. It does not follow that a supplement has the same effect in humans as exercise or metformin.

SIRT1 activation

SIRT1 is an NAD+-dependent deacetylase that influences gene regulation and mitochondrial processes, among other things. How resveratrol affects SIRT1 is complex and has been studied experimentally. Observations in people with certain gene variants do not fully explain these mechanisms. No established anti-aging effect can be derived from them.

Effects on inflammation-related and antioxidant pathways such as NF-κB and Nrf2 have also been described in experimental models. Mechanisms like these raise research questions, but they are no substitute for clinical proof of effectiveness in cardiovascular or neurodegenerative disease.

Dose, formulation and timing according to studies

For comparing products, information on the ingredient, the amount and the quality is helpful. A label such as “98% trans-resveratrol” describes purity; it is not evidence of a health benefit. Higher bioavailability from a special formulation does not, on its own, prove a better clinical effect either.

The doses studied vary widely. They do not support a general recommendation of 250–500 mg for healthy people or 500–1,000 mg for metabolic disorders. A pharmacokinetic study does not establish an effective treatment dose. Anyone considering resveratrol for a medical condition should discuss it with the professional treating them. Source link

A high-fat meal does not reliably improve absorption. In a small study of eight healthy adults taking 2,000 mg twice daily, a high-fat breakfast reduced total exposure by 45% and peak concentration by 46% compared with a standard breakfast. This high-dose study does not support any general recommendation on timing or on splitting a dose. Primary study

Combinations with NMN, quercetin or piperine are on the market, but no reliable added health benefit has been shown. In the human study mentioned above, quercetin did not change resveratrol exposure. Piperine can affect drug metabolism, so it makes sense to check with a professional before combining it with prescription medication. Primary study

Who might benefit and who should be cautious

People with metabolic disorders are an important group in the research. Some studies show favorable changes in individual measurements, others do not. Whether this adds up to a noticeable or long-term health benefit remains open, and it does not replace standard treatment and exercise.

A study of 30 older adults with impaired glucose regulation found better results on a vascular function test after six weeks each on 2–3 g per day, but no improvement in glucose tolerance or insulin sensitivity. It does not prove that older people benefit more than younger people. When several medications are taken at once, possible interactions deserve particular attention. Source link

Experimental findings on platelet function justify caution with anticoagulants and antiplatelet drugs; the actual additional bleeding risk has not been reliably quantified in clinical terms. In 42 healthy adults, 1 g of resveratrol per day for four weeks changed the activity of several CYP enzymes, including CYP3A4, CYP2D6 and CYP2C9. That makes drug interactions plausible, but it does not establish every individual drug combination. With warfarin, aspirin, clopidogrel or other long-term medication, use should be cleared beforehand. Primary study

Pregnant and breastfeeding women should avoid resveratrol supplements because safety data are insufficient. Resveratrol has estrogenic activity in some tissues, and its effects on fetal development and infant health are not well understood.

Assessing metabolic changes with biomarkers

The effects of resveratrol on metabolic health can be tracked with a combination of glucose, insulin, lipid and inflammatory markers. These values can show whether measurable physical changes occur while it is being taken.

Fasting glucose and HbA1c are used to assess glucose metabolism. Fasting insulin and HOMA-IR are added in certain clinical or research settings. A value that differs before and after use does not by itself prove that resveratrol is the cause: diet, exercise, medication and natural fluctuation also play a role.

Lipid markers, including LDL cholesterol, HDL cholesterol and triglycerides, can also shift with resveratrol supplementation, although the size of the change is usually small. Apolipoprotein B (ApoB), which reflects the total number of atherogenic lipoprotein particles, is a more precise marker of cardiovascular risk than LDL cholesterol alone.

High-sensitivity C-reactive protein (hs-CRP) is a marker of systemic inflammation. Resveratrol’s anti-inflammatory effect may show up as lower hs-CRP, especially in people with raised starting values. Other inflammatory markers such as IL-6 and TNF-α are measured less often in routine clinical practice, but they can be relevant in research or in the context of specialized testing.

Which tests and intervals make sense depends on the condition and its treatment. A general monitoring interval of 8 to 12 weeks specifically for resveratrol has not been established. Healthy people do not automatically need extra lab panels just because they plan to take it.

Establishing your metabolic baseline

Research on resveratrol produces interesting but inconsistent results. Baseline values can help assess an existing metabolic disorder; they do not reliably predict who will benefit from resveratrol. Testing should be guided by a specific medical question.

Frequently asked questions

What is the difference between trans-resveratrol and cis-resveratrol?

They are spatially different forms of the same molecule. Trans-resveratrol has been studied clinically far more often. That does not support the sweeping claim that cis-resveratrol is ineffective. Nor does the trans share directly predict how useful a product will be.

Why does resveratrol have such poor bioavailability despite good absorption?

The gut and liver rapidly convert the absorbed substance. In a small study, at least 70% of a 25 mg dose was absorbed, while only traces of unchanged resveratrol appeared in the blood. Concentrations and half-life depend on the product studied and the dose. Study

What trans-resveratrol dose is actually used in clinical studies?

Depending on the research question, doses range from small amounts to several grams per day. That is not a recommendation for everyday use. No generally effective and long-term safe dose for health prevention has been established, and purity claims on the label do not change that.

How does resveratrol activate the SIRT1 and AMPK pathways?

Experimental work describes several direct and indirect effects on cellular energy regulation. The processes depend on concentration and on the model. These mechanisms prove neither an effect comparable to exercise nor that a supplement extends life.

Who benefits most from resveratrol supplementation?

No reliably identifiable group has been established so far. In diabetes and other metabolic disorders, there are both positive and negative study results. Age alone does not predict a benefit either: the study in older people cited here improved a measure of vascular function, but not glucose regulation.

Does taking more resveratrol always lead to better results?

No. A general optimal dose or U-shaped response curve cannot be derived from the sources reviewed here. At 2.5 and 5 g per day, gastrointestinal complaints were observed in a short-term study. Higher blood levels are not evidence of greater health benefit.

What drug interactions should be considered?

A human study showed changes in several drug-metabolizing CYP enzymes. Anyone on long-term medication should therefore check with a professional, especially for drugs with a narrow therapeutic range. Experimental effects on platelets justify extra caution with blood thinners; the exact clinical bleeding risk is not known.

Which biomarkers are suitable for monitoring?

In an existing metabolic disease, the glucose and blood lipid values that are medically useful anyway can be tracked. Additional insulin or inflammation tests are not needed for everyone. Without control conditions, a before-and-after comparison does not prove that resveratrol caused a change.

Sources and literature from the source text

• Brown K, Theofanous D, Britton RG, Aburido G, Pepper C, Sri Undru S, Howells L (2024). Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International journal of molecular sciences, 25(2). https://doi.org/10.3390/ijms25020747 Source link

• Szymkowiak I, Marcinkowska J, Kucinska M, Regulski M, Murias M (2025). Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data. Phytotherapy research : PTR, 39(1), 453-464. https://doi.org/10.1002/ptr.8379 Source link

• Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS, Alzheimer’s Disease Cooperative Study (2015). A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 85(16), 1383-91. https://doi.org/10.1212/WNL.0000000000002035 Source link

• Gu W, Geng J, Zhao H, Li X, Song G (2022). Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. International journal of clinical practice, 2022, 9734738. https://doi.org/10.1155/2022/9734738 Source link

• Abdollahi S, Vajdi M, Meshkini F, Vasmehjani AA, Sangsefidi ZS, Clark CCT, Soltani S (2023). Resveratrol may mildly improve renal function in the general adult population: A systematic review and meta-analysis of randomized controlled clinical trials. Nutrition research (New York, N.Y.), 113, 1-13. https://doi.org/10.1016/j.nutres.2023.03.002 Source link

• Gambino R, Fanni G, Togliatto G, Ponzo V, Goitre I, Cassader M, Brizzi MF, Bo S (2019). Rs12778366 single nucleotide polymorphism of Sirtuin 1 (SIRT1) and response to resveratrol supplementation in patients with type 2 diabetes mellitus. Acta diabetologica, 56(8), 963-966. https://doi.org/10.1007/s00592-019-01341-6 Source link

• Cao X, Liao W, Xia H, Wang S, Sun G (2022). The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrients, 14(18). https://doi.org/10.3390/nu14183755 Source link

• Pollack RM, Barzilai N, Anghel V, Kulkarni AS, Golden A, O’Broin P, Sinclair DA, Bonkowski MS, Coleville AJ, Powell D, Kim S, Moaddel R, Stein D, Zhang K, Hawkins M, Crandall JP (2017). Resveratrol Improves Vascular Function and Mitochondrial Number but Not Glucose Metabolism in Older Adults. The journals of gerontology. Series A, Biological sciences and medical sciences, 72(12), 1703-1709. https://doi.org/10.1093/gerona/glx041 Source link

Evidence status: The incorrect attributions of the kidney and lipid meta-analyses were corrected in the main text. The observational study on the SIRT1 gene variant is no longer used as evidence for a mechanism; its full text could not be consulted for this review.

• Additional primary sources: Walle et al., 2004; la Porte et al., 2010; Brown et al., 2010; Chow et al., 2010.

Origin and editorial review status

Translated and adapted for Nutrient Desk from the source article. Promotional membership, newsletter and lab offers were removed. The bibliography is kept in its original form so that each work can be identified unambiguously. Claims and source attributions were editorially checked against accessible studies and corrected. Remaining limitations are documented in the evidence report. This draft is not approved for indexing.